CTLA4 and neoplasm: While chemotherapy acts directly on cancer cells inhibiting the cell cycle, ICIs are antibodies targeting the programmed death 1 (PD-1), programmed death-ligand (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), blocking key regulatory signals that dampen immune responses in the tumour microenvironment.